)
Edge
Extra Everything: The Story of Chipotle
Chipotle's story from a single restaurant to a nationwide chain, through crisis and turnaround, built on one of the strongest models in the industry.
IN8bio
IN8bio (INAB) investor relations material
IN8bio Q1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 2026 earnings summary7 May, 2026
Executive summary
Focused on gamma-delta/yō T cell therapies for cancer and autoimmune diseases, with lead programs INB-100 (AML) and INB-200/400 (glioblastoma) in clinical development.
INB-100 Phase 1 completed primary enrollment; expansion cohort ongoing, with long-term data expected late 2026.
INB-400 Phase 2 enrollment suspended to conserve capital; further development contingent on funding or partnerships.
Advanced next-generation yō T cell engager platform, with initial animal data expected in 2026.
Reported glioblastoma data showing 97% improvement in progression-free survival versus standard-of-care; updated median overall survival data to be presented at ASCO 2026.
Financial highlights
Cash as of March 31, 2026: $21.9 million, down from $27.1 million at December 31, 2025, but up from $11.9 million year-over-year.
Net loss for Q1 2026: $5.1 million ($0.26 per share), improved from $5.6 million ($2.16 per share) in Q1 2025.
Research and development expenses decreased to $2.6 million from $3.0 million year-over-year, mainly due to lower clinical trial and facility costs.
General and administrative expenses stable at $2.7 million year-over-year.
No revenue generated; operations funded by equity and warrant issuances.
Outlook and guidance
Existing cash is not expected to fund operations for 12 months from the report date; substantial doubt about ability to continue as a going concern.
Management pursuing additional capital via equity, debt, or strategic partnerships; up to $20.1 million in potential milestone-driven proceeds from private placement and up to $9 million from warrant exercises, but no assurance of receipt.
Anticipates FDA guidance on accelerated regulatory pathways for the GBM program in 2H26 and plans to publish Phase 1 INB-200 clinical data.
Expects initial TCE preclinical animal data and additional IND-enabling data for INB-619 in 2H26.
Cash preservation measures in place, impacting timing of milestones and regulatory filings.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from IN8bio
- Gamma delta T cell therapies and novel engagers show strong efficacy and safety, with major milestones ahead.INAB
Biotech Resurgence: Platforms and Pipelines of Today's Innovators16 Apr 2026 - Virtual meeting to elect directors, ratify auditor, and approve equity plan on May 7, 2026.INABProxy filing26 Mar 2026
- Annual meeting to vote on director elections, auditor ratification, and expanded equity plan.INABProxy filing26 Mar 2026
- Durable remissions and superior safety achieved with γδ T cell therapies in oncology trials.INABInvestor presentation23 Mar 2026
- Clinical progress in glioblastoma and improved financials set up key milestones for 2026.INABQ4 202513 Mar 2026
- Repeat gamma delta T cell dosing in glioblastoma yields superior survival and safety outcomes.INABTD Cowen 46th Annual Health Care Conference2 Mar 2026
- Gamma-delta T cell therapies show durable remissions and major survival gains in glioblastoma.INABNoble Capital Markets’ Emerging Growth Virtual Equity Conference5 Feb 2026
- Durable remissions and broad immune targeting drive optimism for upcoming gamma delta T cell data.INABH.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference3 Feb 2026
- INB-100 prioritized for leukemia after strong early results; other programs paused amid funding challenges.INABH.C. Wainwright 26th Annual Global Investment Conference 202421 Jan 2026
Next IN8bio earnings date
Status update21 May, 2026
IN8bio
Next IN8bio earnings date
Status update21 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
)
Frequently asked questions
Explore our global coverage